Showing results (31-40 of 187) with videos related to
Sort By:
Pageof 19
Diabetic Medicine : a Journal of the British Diabetic Association|May 25, 2002
A comparison of the Neuropen against standard quantitative sensory-threshold measures for assessing peripheral nerve functionA N Paisley, C A Abbott, C H M van Schie, et al.Clinical Endocrinology|November 21, 2008
Long-term experience of pegvisomant therapy as a treatment for acromegalyC E Higham, T T Chung, J Lawrance, et al.The Journal of Clinical Endocrinology and Metabolism|April 16, 2009
Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegalyC E Higham, S Rowles, D Russell-Jones, et al.The Journal of Endocrinology|September 1, 1992
Pyridostigmine partially reverses dexamethasone-induced inhibition of the growth hormone response to growth hormone-releasing hormoneP J Trainer, J M Kirk, M O Savage, et al.Clinical Endocrinology|April 18, 2007
Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practiceA Pokrajac, G Wark, A R Ellis, et al.European Journal of Endocrinology|May 5, 2009
Successful use of weekly pegvisomant administration in patients with acromegalyC E Higham, J D J Thomas, M Bidlingmaier, et al.Clinical Endocrinology|October 1, 1993
The relationship between cortisol production rate and serial serum cortisol estimation in patients on medical therapy for Cushing's syndromeP J Trainer, C Eastment, A B Grossman, et al.Nuclear Medicine Communications|July 1, 1992
A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG)K K Solanki, J Bomanji, J Moyes, et al.Clinical Endocrinology|April 10, 2002
Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegalyC Parkinson, W M Drake, G Wieringa, et al.Pageof 19